Aerovate Therapeutics, Inc. has entered into a merger agreement with Jade Biosciences, Inc., where Jade will merge into Aerovate, resulting in Jade stockholders owning approximately 98.4% of the combined company, and Aerovate plans to declare a cash dividend of about $65 million to its stockholders.